At a glance: Bad news for Astra-Zeneca’s Exanta
AstraZeneca’s oral anticoagulant drug – what’s the story? The US Food and Drug Administration (FDA) last week refused approval for Exanta in any form. The company put forward three indications for the drug, including its use to treat blood clots after knee surgery.
Sign in to continue
Need to activate your subscription?
Domain/Group Subscriptions
Click here >>
Individual Subscriptions
Click here >>
Need to activate your Subscription
Company Wide Subscriptions
Click here >>
UK Individual Subscribers
Click here >>